default author photo

Florian Kaiser

affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

68

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

FOLFIRI with Cetuximab or Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer: Refining First-Line Treatment Selection by Combining Clinical Parameters - A post hoc Analysis of the Randomized Open-Label Phase III Trial FIRE-3/AIO KRK0306

Number of pages: 25 Posted: 20 Feb 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, Charité–Universitätsmedizin Berlin, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Charité–Universitätsmedizin Berlin, Gesundheitszentrum St. Marien, HOPE—Practice for Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Rostock - Rostock University Medical Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Johannes Gutenberg University Mainz - I. Med. Klinik und Poliklinik, Charité–Universitätsmedizin Berlin, University of Melbourne and LMU Munich - Department of Hematology/Oncology
Downloads 68 (891,180)

Abstract:

Loading...

metastatic colorectal cancer, primary tumor sidedness, metastatic pattern, liver-limited disease, predictive biomarker, biomarker combination, comprehensive statisticalmodelling, FOLFIRI, cetuximab, bevacizumab